News
The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.
Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be ...
Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US ...
Germany’s Merck agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid ...
German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer ...
Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...
After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.
Current health news highlights include a dispute over EU drug pricing proposals, a U.S.-Mexico accord on screwworm management ...
Novartis released a more optimistic full-year earnings forecast on Tuesday, citing the strong growth of drugs such as Leqvio, ...
Merck KGaA, Darmstadt, Germany, a science and technology company, has entered into a definitive agreement to acquire ...
U.S. stock futures are little changed as investors ready for a busy earrings calendar, including upcoming reports from Apple, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results